{
    "organizations": [],
    "uuid": "d8067281e73fad0ffcb39395435fe690cc064d3a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cannaroyalty-and-aequus-pharmaceut/brief-cannaroyalty-and-aequus-pharmaceuticals-announce-jv-to-develop-and-commercialize-cannabis-based-therapies-targeting-neurological-disorders-idUSFWN1P60E6",
    "ord_in_thread": 0,
    "title": "BRIEF-Cannaroyalty And Aequus Pharmaceuticals Announce JV To Develop And Commercialize Cannabis-Based Therapies Targeting Neurological Disorders",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 10 AM / Updated 15 minutes ago BRIEF-Cannaroyalty And Aequus Pharmaceuticals Announce JV To Develop And Commercialize Cannabis-Based Therapies Targeting Neurological Disorders Reuters Staff 1 Min Read \nJan 11 (Reuters) - Aequus Pharmaceuticals Inc: \n* CANNAROYALTY AND AEQUUS PHARMACEUTICALS ANNOUNCE JOINT VENTURE TO DEVELOP AND COMMERCIALIZE CANNABIS-BASED THERAPIES TARGETING NEUROLOGICAL DISORDERS Source text for Eikon: Further company coverage:",
    "published": "2018-01-11T13:10:00.000+02:00",
    "crawled": "2018-01-11T13:31:31.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "aequus",
        "pharmaceutical",
        "announce",
        "jv",
        "develop",
        "commercialize",
        "therapy",
        "targeting",
        "neurological",
        "disorder",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "aequus",
        "pharmaceutical",
        "inc",
        "cannaroyalty",
        "aequus",
        "pharmaceutical",
        "announce",
        "joint",
        "venture",
        "develop",
        "commercialize",
        "therapy",
        "targeting",
        "neurological",
        "disorder",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}